Is Desh Rakshak overvalued or undervalued?

As of 23 October 2025, the valuation grade for Desh Rakshak has moved from risky to fair. The company is currently fairly valued, with a PE ratio of 34.40, an EV to EBITDA of 15.42, and a PEG ratio of 0.62. In comparison to peers, Sun Pharma is considered expensive with a PE of 35.47, while Cipla is attractive with a PE of 24.64, indicating that Desh Rakshak is positioned reasonably within its industry.
Despite a recent decline in stock price, with a 1-month return of -14.23% compared to the Sensex's 2.99%, the company has shown strong performance year-to-date with a return of 241.46%. The overall metrics suggest that while Desh Rakshak is not undervalued, it is fairly positioned in the market relative to its peers.